Product Description
Ricolinostat is an orally bioavailable, specific inhibitor of histone deacetylase 6 (HDAC6) with potential antineoplastic activity. Ricolinostat selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system through hyperacetylation of Hsp90 and preventing the subsequent aggresomal protein degradation. This leads to an accumulation of unfolded and misfolded ubiquitinated proteins and may eventually induce cancer cell apoptosis, and inhibition of cancer cell growth. HDAC6, a class II HDAC deacetylase located in the cytoplasm, appears to play a key role in the formation and activation of the aggresomes needed for degradation of misfolded proteins. Compared to non-selective HDAC inhibitor, ACY-1215 is able to reduce the toxic effects on normal, healthy cells. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Ricolinostat)
Mechanisms of Action: HDAC6 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 2: Peripheral Nervous System Diseases
Phase 1: Chemotherapy-induced Peripheral Neuropathy|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT02787369 | P1 |
Active, not recruiting |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2026-04-01 |
|
| BCRG-CN-101 | P1 |
Completed |
Peripheral Nervous System Diseases |
2023-11-10 |
|
| REGY-DN-201 | P2 |
Completed |
Peripheral Nervous System Diseases |
2022-10-31 |
|
| BCRG-CN-102 | P1 |
Completed |
Peripheral Nervous System Diseases |
2022-01-30 |